Amplified in breast cancer 1 (AIB1) can promote the tumorigenesis, development and metastasis in breast cancer. However, the association between AIB1 expression and the tumorigenesis and development of ovarian cancer is still not clear. In this study, we extracted the mRNA expression data of ovarian cancer tissues from TCGA database, and analyzed the correlation between aib1 expression and overall survival (OS), post progression survival (PPS) and progression free survival (PFS) in ovarian cancer patients by using online software Kaplan-Meier plotter. Results showed that OS, PPS and PFS were significantly reduced in patients with aib1 high expression in both all patient population and the DDP-treated population. In SKVO3 cell line transfected with AIB1 over expression plasmid and siRNA was found to up-regulate and down-regulate AIB1 expression respectively, and then the sensitivity of cells to DDP (cis-dichlorodiammine platinum, DDP) was detected. Results showed that up-regulation of AIB1 inhibited the sensitivity of SKVO3 cells to DPP, whereas down-regulation of AIB1 promoted the sensitivity of SKVO3 cells to DPP. Further study showed that the high expression of AIB1 up-regulated the expression of anti-apoptotic proteins B-cell lymphoma-2 (BCL2) and B-cell lymphoma/leukemia x long form (BCL2L1) in SKVO3 cells, while the depletion of AIB1 down-regulated the expression of BCL2 and BCL2L1 in ovarian cancer cells. The mRNA expression data of cancer tissues from ovarian cancer patients was extracted from the TCGA database, and the association between aib1 mRNA levels and the mRNA expression of bcl2 and bcl2l1 was analyzed by online software GEPIA. We found that aib1 expression was positively correlated with bcl2 and bcl2l1 expression. These results further suggested that AIB1 might regulate the expression of BCL2 and BCL2L1. Altogether, our results showed that AIB1 could be used as a potential marker for the prognosis of ovarian cancer and a potential molecular target for the treatment of ovarian cancer. Moreover, this study also found that inhibition of AIB1 can enhance the therapeutic effect of DDP in ovarian cancer. This study provided new insights for the pathogenesis of ovarian cancer resistance to DDP, and has certain value for overcoming ovarian cancer chemotherapy resistance.